Unloved once more: the health stocks to snap up | Money

On those days when we stood outside our doors clanking saucepans and clapping for the NHS, it seemed that the days of taking healthcare professionals for granted were finally over.

And it was not just the NHS that had a boost at the start of the pandemic, it was healthcare stocks too. Who remembers Novacyt, the Southampton-based PCR test-maker? Its shares rose 7,000 per cent as testing was rolled out. Now they are down 80 per cent from their peak and the firm is involved in an ugly spat with the government over contracts.

Investors are a tough crowd and haven’t shared the public’s appreciation of healthcare (and biotechnology companies in particular), but some of the valuations seem harsh so there could be some bargains

Leave a Comment

Your email address will not be published.